Literature DB >> 25689880

Modified liver-free multivisceral transplantation for a metastatic small bowel neuroendocrine tumor: a case report.

A Frilling1, H Giele2, G Vrakas3, S Reddy3, R Macedo3, A Al-Nahhas4, H Wasan5, A K Clift6, G E Gondolesi7, R M Vianna8, P Friend3, A Vaidya3.   

Abstract

Neuroendocrine tumors originating from the small bowel frequently metastasize to the lymph nodes and/or liver. Although surgical extirpation of the primary tumor and locoregional metastases epitomizes the management of patients with such tumors, this is not always possible with conventional surgical techniques. Nonresectable, slow-growing tumors involving the mesenteric root represent a generally accepted indication for deceased donor intestinal and multivisceral transplantation. Furthermore, vascularized sentinel forearm flaps offer opportunities for monitoring graft rejection and tailoring immunosuppression regimens. Here, we report the first documented case of modified liver-free multivisceral transplantation preceded by neoadjuvant 177-lutetium peptide receptor radionuclide therapy in a patient with a small bowel neuroendocrine tumor and extensive lymph node metastases in the mesenterium. At a follow-up of 21 months the patient is biochemically and radiologically disease-free.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25689880     DOI: 10.1016/j.transproceed.2015.01.007

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

1.  Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours.

Authors:  Ashley Kieran Clift; Omar Faiz; Adil Al-Nahhas; Andreas Bockisch; Marc Olaf Liedke; Erik Schloericke; Harpreet Wasan; John Martin; Paul Ziprin; Krishna Moorthy; Andrea Frilling
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

Review 2.  Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Rafał Stankiewicz; Michał Grąt
Journal:  World J Gastrointest Surg       Date:  2022-04-27

Review 3.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

4.  Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems.

Authors:  Ashley K Clift; Omar Faiz; Robert Goldin; John Martin; Harpreet Wasan; Marc-Olaf Liedke; Erik Schloericke; Anna Malczewska; Guido Rindi; Mark Kidd; Irvin M Modlin; Andrea Frilling
Journal:  Endocr Connect       Date:  2017-01-19       Impact factor: 3.335

Review 5.  Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours.

Authors:  Ashley Kieran Clift; Andrea Frilling
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

6.  Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation for an advanced small intestinal neuroendocrine neoplasm: an updated case report.

Authors:  Ashley K Clift; Henk Giele; Srikanth Reddy; Rubens Macedo; Adil Al-Nahhas; Harpreet S Wasan; Gabriel E Gondolesi; Rodrigo M Vianna; Peter Friend; Anil Vaidya; Andrea Frilling
Journal:  Innov Surg Sci       Date:  2017-08-25

7.  Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Halil Komek; Tansel Ansal Balci; Canan Can
Journal:  Asia Ocean J Nucl Med Biol       Date:  2019

Review 8.  Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.

Authors:  Andrea Lania; Francesco Ferraù; Manila Rubino; Roberta Modica; Annamaria Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-26       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.